Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...
A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...
Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...
While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...
Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for ...
Incyte (INCY) stock and Xencor (XNCR) stock are in focus as jointly developed antibody drug tafasitamab succeeds in a ...
A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
Rockville, Maryland Friday, January 9, 2026, 10:00 Hrs [IST] ...
US biotech Incyte (Nasdaq: INCY) yesterday announced positive top-line results from the pivotal Phase III frontMIND trial ...
Everyday Health on MSN
Who should be on your large B-cell lymphoma care team?
Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback